Copyright © 2004 by the European Society of Cardiology.
Clinical research
Response to programmed ventricular stimulation and clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter defibrillator or antiarrhythmic drug therapy
a Arrhythmia and Electrophysiology Center, Istituto Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy
b AK S. Georg, Hamburg, Germany
Received October 2, 2003;
revised December 10, 2003;
accepted January 15, 2004
* Corresponding author. Tel.: +39-2-5277-4450; fax: +39-2-5560-3125
E-mail address: rcappato{at}libero.it
See page 623 for the editorial comment on this article1
Background Using a prospective design which randomly assigned implantable cardioverter defibrillator (ICD) versus antiarrhythmic drugs (AADs), we investigated the usefulness of programmed ventricular stimulation (PVS) for prediction of outcome and therapy effectiveness in cardiac arrest (CA) survivors.
Methods and results We performed baseline PVS in 285 survivors of CA enrolled in the Cardiac Arrest Study Hamburg (CASH) and randomised to ICDs or AADs. Sustained ventricular arrhythmia (VA) was induced in 134 (47.0%) patients. We compared the outcomes of different subgroups based on response to baseline PVS and randomly assigned therapy. Patients were followed for a median of 55 months. The raw death rate was greater among inducible (51.3% [95% CI: 44.9–58.3%]) than non-inducible patients (28.8% [CI: 23.4–36.1%, 
]). When challenged in a multivariate model, inducibility still had an independent power for predicting all-cause death (hazard ratio (HR), 1.5 [95% CI, 1.1–2.3], 
), but not sudden death (SD) (HR, 1.2 [95% CI, 0.7–3.6], 
). Subgroup analysis showed that, when compared to AADs, assignment to ICDs was associated with a lower risk of all-cause death (HR, 0.4 [95% CI, 0.1–0.9], 
) in patients with EF
0.35 and non-inducible arrhythmias, but not in other patient subgroups.
Conclusions In CA survivors, inducibility at baseline PVS is independently associated with an increased risk of all-cause death, but not SD. In addition, response to PVS may help to identify subgroups of patients who could most benefit from ICD.
Key Words: Electrophysiological testing • Cardiac arrest • Implantable defibrillator • Antiarrhythmic therapy
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Treating electrical instability in sudden cardiac death survivors – are we looking at the right side of the coin?
- H Weber, K Allikmets, and G Kornfeld
EHJ 2004 25: 623-625.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  J M Morgan, J C Cowan, A J Camm, and J M McComb Sudden cardiac death: opportunities for prevention Heart, June 1, 2006; 92(6): 721 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rotter, Y. Takahashi, P. Sanders, M. Haissaguerre, P. Jais, L.-F. Hsu, F. Sacher, J.-L. Pasquie, J. Clementy, and M. Hocini Reduction of fluoroscopy exposure and procedure duration during ablation of atrial fibrillation using a novel anatomical navigation system Eur. Heart J., July 2, 2005; 26(14): 1415 - 1421. [Abstract] [Full Text] [PDF]
|
|